Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
Mark Underwood, Joe Horton, Keith Nangle, Judy Hopking, Kimberly Smith, Michael Aboud, Brian Wynne, Jörg Sievers, Eugene L. Stewart, Ruolan Wang
Abstract
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. Here, we report emergent HIV-1 drug resistance and mechanistic underpinnings among dolutegravir-treated adults in DAWNING.
Topics & Concepts
DolutegravirIntegraseVirologyIntegrase inhibitorNucleoside Reverse Transcriptase InhibitorReverse transcriptaseMedicineNucleosideDrug resistanceViral replicationPopulationNucleoside analogueElvitegravirRaltegravirVirusHuman immunodeficiency virus (HIV)Reverse-transcriptase inhibitorPharmacologyBiologyPhases of clinical researchLentivirusDrugNucleotidyltransferaseViral loadSalvage therapyHIV/AIDS drug development and treatmentHIV-related health complications and treatmentsBiochemical and Molecular Research